Randomized treatment trial for adenoviral conjunctivitis
Phase 3
Completed
- Conditions
- Health Condition 1: H102- Other acute conjunctivitis
- Registration Number
- CTRI/2023/08/056723
- Lead Sponsor
- Sadguru Netra Chikitsalaya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Treatment naïve patients with recent onset of the presumed viral conjunctivitis (presenting within 5 days) and consenting to participate in the study will be included.
Exclusion Criteria
Patients with age <8 years, diffuse hemorrhagic conjunctivitis, conjunctivitis having matted eyelashes/ purulent discharge/ membrane or pseudo membrane/ lid infections like stye and chalazion, corneal involvement, anterior segment inflammation, prior history of viral keratitis, glaucoma or steroid responder, who do not adhere to the study follow- up schedule and mentally subnormal patients who are unable to express symptoms severity will be excluded
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is the proportion of patients getting complete relief (symptom score 0) in the ‘study eye’ after 48 hours & 7 days of starting treatment.Timepoint: 48 hours & 7 days of starting treatment
- Secondary Outcome Measures
Name Time Method Partial relief in terms of reduction of symptom scoresTimepoint: 48 hours & 7 days of starting treatment;proportion of patients developing adverse events & the subsequent need for change in treatment.Timepoint: 48 hours & 7 days of starting treatment